People · Operator
Named in public records as an officer, director or promoter · active 2018–2024 · Biotech / Pharma, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| BlueSphere Bio, Inc. | — | Biotech / Pharma | Series C | $55.6M | $1.5B | 2018 |
| Xealth Inc. | — | Other Technology | Series B | $50.1M | $29.3M | 2024 |
Tal Heppenstall at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Tal Heppenstall on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jeanne Cunicelli | 1 | 7 |
| Daniel Galles | 1 | 5 |
| WILLIAM BRYANT | 1 | 4 |
| Aaron Martin | 1 | 4 |
| MARK STABINGAS | 1 | 3 |
| Aaron Sheedy | 1 | 2 |
| David Apelian | 1 | 2 |
| Leslie Wyles | 1 | 2 |
| Michael McSherry | 1 | 2 |
| Robert Lin | 1 | 2 |
| Katie Scott | 1 | 1 |
| Sundar Balasubramanian | 1 | 1 |
| Eric Fu | 1 | 1 |
| Warren Shlomchik | 1 | 1 |
| Mark Shlomchik | 1 | 1 |
| Alan Korman | 1 | 1 |
| Rasu Shrestha | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.